Open AccessCombination of ibrutinib and venetoclax followed by Chimeric Antigen Receptor T-cell therapy in the first line of treatment in an elderly patient with mantle cell lymphoma with hyperleukocytosis and mutation in the TP53 gene
Author(s) -
Е Е Звонков,
Daria Koroleva,
Nelly G. Gabeeva,
А. Е. Щекина,
M. A. Telyashov,
O A Gavrilina,
Б В Бидерман,
Andrey Sudarikov,
Tatiana Obukhova,
Irina Galtseva,
V. N. Dvirnik,
Vera V. Troitskaya,
G. М. Galstyan,
Michael Maschan,
Е Н Паровичникова
Publication year - 2022
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2022-67-3-441-452
Subject(s) - ibrutinib , mantle cell lymphoma , venetoclax , medicine , chimeric antigen receptor , lymphoma , oncology , bendamustine , cancer research , gastroenterology , leukemia , chronic lymphocytic leukemia , cancer , rituximab , immunotherapy